Not yet recruiting
Breast cancer
Not yet recruitingStudy Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence
Registered drugNo placebo
Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence
Registered drugNo placebo
- Disease:Breast cancer
- Substances:AnastrozoleExemestane+3
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Eli Lilly & Co.



